SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerSCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer, Published online: 13 November 2018; doi:10.1038/s41416-018-0319-zSCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

Source: British Journal of Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Jos é Robles-Zurita Kathleen A. Boyd Andrew H. Briggs Timothy Iveson Rachel S. Kerr Mark P. Saunders Jim Cassidy Niels Henrik Hollander Josep Tabernero Eva Segelov Bengt Glimelius Andrea Harkin Karen Allan John McQueen Sarah Pearson Ashita Waterston Loui Source Type: research